New multi-biomarker test accurate in detection of clinically significant prostate cancer

A newly published study in The Lancet Oncology has provided some very interesting data on the accuracy of a new, multi-biomarker test in screening 50- to 69-year-old men for risk of prostate cancer. … READ MORE …

Screening and the incidence of newly diagnosed, metastatic prostate cancer over time

Another article in this week’s issue of the New England Medical Journal is going to re-fuel the fire among those who advocate for widespread, frequent screening of men for risk of prostate cancer. … READ MORE …

The utility and value of new imaging techniques in advanced prostate cancer

PET/CT scans using the radioactive fluorinated inhibitor of prostate-specific membrane antigen (PSMA) known as 18F-DCFBC (or just DCFBC) are better at detecting metastases … READ MORE …

The direct “financial toxicity” of cancer diagnosis and treatment

An interesting new paper in Cancer has offered us a sophisticated assessment of the effects of a diagnosis of and treatment for cancer on employment and income of all adults (aged 18 and older) and of adults in their  prime working years (aged from 25 and 64). … READ MORE …

Risk levels and family history of prostate cancer: data from the Swiss cohort of the ERSPC

Data just published in BJU International have recently suggested that men with a known, positive family history of prostate cancer are certainly at increased risk of low-grade prostate cancer compared to men with no known family history — but not at increased risk of aggressive prostate cancer. … READ MORE …

Testosterone therapy and risk for prostate cancer (redux)

The question of whether long-term exposure to testosterone therapy is associated with a significant increase in risk for a diagnosis of prostate cancer (and particularly clinically significant or high-risk prostate cancer) remains a matter of debate. … READ MORE …

Introducing PI-RADS version 2: application of multiparametric MRI scans for prostate cancer risk assessment

PI-RADS™ stands for Prostate Imaging and Reporting and Data System and is a system used to guide standardization and limit variation in the performance, interpretation, and reporting of prostate MRI exams prior to any form of active treatment. … READ MIORE …

Follow

Get every new post delivered to your Inbox.

Join 1,367 other followers